Navigation Links
Transcept Pharmaceuticals to Present at the BioCentury 'Future Leaders in the Biotech Industry' Conference
Date:3/19/2008

PT. RICHMOND, Calif., March 19 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the BioCentury "Future Leaders in the Biotech Industry" Conference at the Millennium Broadway Hotel & Conference Center in New York City on Thursday, March 27, 2008 at 9:30 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Transcept Pharmaceuticals to Present at Cowen and Companys 27th Annual Health Care Conference in Boston
2. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
3. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
4. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
6. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
7. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
10. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
11. Waters Offers U.S. Water Authorities Complimentary Drinking Water Testing for the Presence of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 2Mach 7 Technologies Contracted by Singapore General Hospital to Provide State-of-the-Art Patient Image Management Technology 3Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer 2Study 3A Oil speculators dominate open interest in oil futures 9713 1Study 3A Oil speculators dominate open interest in oil futures 9713 2Study 3A Oil speculators dominate open interest in oil futures 9713 3Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 55519 1Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 55519 2Keep Oral Health in Check This School Year With the New Philips Sonicare for Kids Power Toothbrush 55519 3IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 55515 1IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 55515 2IDRI Initiates Therapeutic Vaccine Clinical Trial in Sudan Against Leishmaniasis 55515 3